Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAN6 versus SHAN5 with polio vaccines in healthy Thai infants
2021-006686-37Phase 3
- Sponsor
- Sanofi
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of DTwP-HepB-Hib-IPV hexavalent vaccine in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoint: Antibody response above predefined thresholds against diphtheria, tetanus, hepatitis B, Haemophilus influenzae type b, and poliovirus antigens.
02
Drugs
DTwP-HepB-Hib-IPV hexavalent vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2021-006686-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006686-37.